The Coming of Age of Monoclonal Antibodies

This article explores the rapid rise of monoclonal antibodies (mAbs) and why they are poised to surpass small-molecule medicines as the backbone of modern therapeutics. It explains how mAbs offer unparalleled precision and potency, outlines their expanding role across disease areas, and highlights how innovations in biosimilars and biomanufacturing are driving costs down and increasing global accessibility.